Poseida Therapeutics Announces Agreement to Be Acquired by Roche for Up to $1.5 Billion
November 27, 2024
November 27, 2024
PALO ALTO, California, Nov. 27 -- Cooley, a law firm, issued the following news release:
San Diego - November 26, 2024 - Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an . . .
San Diego - November 26, 2024 - Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an . . .